DIFFUSION PHARMACEUTICALS IN (DFFN) Stock News

USA - NASDAQ:DFFN - US2537484048 - Common Stock

4.4 USD

+0.46 (+11.68%)

Last: 8/16/2023, 8:00:02 PM

4.46 USD

+0.06 (+1.36%)

After Hours: 8/16/2023, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DFFN Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

3 years ago - By: Benzinga

Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow

3 years ago - By: Benzinga

Why Diffusion Pharmaceuticals Shares Are Falling

3 years ago - By: Kahn Swick & Foti, LLC

DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN

3 years ago - By: Halper Sadeh LLC

DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders

3 years ago - By: Seeking Alpha

Diffusion to merge with EIP Pharma in all-stock deal

3 years ago - By: Diffusion Pharmaceuticals Inc.

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

3 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

4 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

4 years ago - By: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders